Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
<h4>Background</h4>Uncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.<h4>Methods</h4>Eligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy for p...
Guardado en:
Autores principales: | Tatsuya Suwabe, Francisco J Barrera, Rene Rodriguez-Gutierrez, Yoshifumi Ubara, Marie C Hogan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6f9ca9a7b2574d088b588da4331f0ab4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Echocardiographic Findings and Genotypes in Autosomal Dominant Polycystic Kidney Disease
por: Ryohei Miyamoto, et al.
Publicado: (2021) -
Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.
por: Tove Lekva, et al.
Publicado: (2013) -
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
por: Adelman DT, et al.
Publicado: (2012) -
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
por: Sendhilnathan Ramalingam, et al.
Publicado: (2021) -
The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
por: Kiyotaka Uchiyama, et al.
Publicado: (2021)